Where is OmiCure located?

OmiCure is headquartered in Cambridge, United States.

How many employees does OmiCure have?

As of Jul 01, 2024, the latest employee count at OmiCure is 5.

Is OmiCure a funded company?

OmiCure is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does OmiCure rank among its competitors?

OmiCure ranks 325th amongst 791 active competitors, of which 140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was NeuroKaire, which secured $10M in Dec, 2024.

Who are the top competitors of OmiCure?

OmiCure's top competitors include Benchling, Helix and Congenica. Among them, NeuroKaire secured the most recent funding round in December, 2024.

OmiCure - 2026 Company Profile, Team & Competitors

Company Details

AI-powered cancer therapy and diet selection using tumor molecular analysis. They empower patients and physicians in the fight against cancer by providing actionable and personalized knowledge. Their service helps clinicians choose personalized therapies and diets based on a tumor's molecular profile, delivering a report with potential treatment and nutriment options. They utilize genomic sequencing, RNA sequencing (RNA-seq), and whole-exome sequencing (WES) coupled with Artificial Intelligence (AI) analysis to compare a tumor's genomic profile against a comprehensive knowledge base. This results in a targeted treatment plan, equipping medical teams with the knowledge to pursue the latest advances in personalized medicine. They offer a software solution that supports informed decision-making in oncology, providing a valuable tool for precision medicine. This is a B2B service for practitioners.

Website: www.omicure.com/
Social

Key Metrics

Founded Year

2003

Location

Cambridge, United States

Stage

Unfunded

Ranked

325^th among 791 active competitors

Employee Count

5 as on Jul 01, 2024

Similar Companies

Benchling & 1031 more

View OmiCure's full profile

OmiCure has not raised any funding rounds yet.

The founders of OmiCure is Thomas Turcat.

Here are the details of OmiCure's key team members:

Thomas Turcat: Co-Founder of OmiCure.
Contact Info: 1 email address

View details of OmiCure's Founder profiles and Board Members

OmiCure's employee count trend

OmiCure has 5 employees as of Jul 24. Here is OmiCure's employee count trend over the years:

Uncover OmiCure's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OmiCure include Benchling, Helix and Congenica. Here is the list of Top 10 competitors of OmiCure, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Benchling 2012, San Francisco (United States), Series F	Provider of a cloud-based bioinformatics platform for biotech research	$412M	Altimeter Capital, Draper & 28 others	73/100
2nd	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
3rd	Congenica 2013, Cambridge (United Kingdom), Acquired	Developer of software for clinical genomic interpretation and variant analysis	$81.9M	IDO Investments, Tencent & 39 others	62/100
4th	Sophia Genetics 2011, Rolle (Switzerland), Public	Provider of artificial intelligence software for analyzing complex medical data	$249M	Generation Investment Management, Endeavour Vision ... & 24 others	62/100
5th	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	Nextech Invest, The Column Group & 10 others	62/100
6th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
7th	NeuroKaire 2017, Kearny (United States), Series A	Platform offering personalized treatment for psychiatric and neurological conditions	$20M	GreyBird Ventures, Meron Capital & 6 others	61/100
8th	Latch 2021, San Francisco (United States), Series A	Provider of a web-based platform for genomic bioinformatics	$33M	Lux Capital, Coatue & 7 others	58/100
9th	BC Platforms 1997, Zurich (Switzerland), Series D	Provider of a platforms for genomic data analysis and management	$47.1M	Jolt Capital, Debiopharm & 6 others	58/100
10th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
325th	OmiCure 2003, Cambridge (United States), Unfunded	AI-powered cancer therapy and diet selection using tumor molecular analysis	-	-	26/100